Status:
TERMINATED
Study of Satraplatin (JM-216) in Combination With Docetaxel
Lead Sponsor:
Agennix
Conditions:
Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a single center, open-label, non-randomized, Phase I dose finding study of the investigational, oral cytotoxic drug, satraplatin (JM-216), in combination with docetaxel in patients with advanc...
Eligibility Criteria
Inclusion
- Histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative chemotherapy measures do not exist or are no longer effective
- Life expectancy of at least 3 months
- Measurable or evaluable disease
- ECOG performance status of \<= 2
- Willingness and ability to give informed consent
Exclusion
- Women who are pregnant or breastfeeding
- Other chemotherapy treatment less than 4 weeks prior to enrollment
- Treatment with docetaxel or a platinum agent less than 3 months prior to enrollment
- Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00125411
Start Date
March 1 2007
End Date
February 1 2009
Last Update
March 26 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, United States, 53792